Alvotech Soars 13% on FDA Nod That “Effectively Doubles” US Humira Biosimilar Capacity
Alvotech's shares surged 13% after the FDA approved a second production suite in Reykjavik for its Humira biosimilar, Simlandi, effectively doubling its U.S. manufacturing capacity. This approval signals that prior factory-related issues, which had led to rejections for other biosimilar applications, may be resolved. Alvotech now anticipates FDA decisions on three re-submitted filings and a fourth new filing in the current quarter, potentially leading to more positive news.
Amgen stock faces a USD 400 Cantor Fitzgerald target
Cantor Fitzgerald maintained a Neutral rating on Amgen with a USD 400 price target, despite the stock trading slightly above this target at USD 403.25. Amgen's Q2 revenue significantly increased by 9.5% year over year, reaching USD 10.05 billion. The analyst consensus for Amgen is a Hold, with an average price target of USD 385.25.
Amgen Inc. $AMGN Shares Purchased by Ferguson Wellman Capital Management Inc.
Ferguson Wellman Capital Management Inc. increased its stake in Amgen Inc. by 4.8% during the third quarter, acquiring an additional 11,950 shares. Several other institutional investors also adjusted their positions in Amgen. The article also details recent insider stock sales, analyst ratings, and Amgen's financial performance.
2,546 Amgen Inc. $AMGN Shares Sold by Argent Capital Management LLC
Argent Capital Management LLC reduced its stake in Amgen Inc. by 3.5% in the third quarter, selling 2,546 shares and holding 69,486 shares valued at $29.29 million. Other institutional investors made various adjustments to their holdings. Analysts have issued mixed ratings on AMGN shares, with a consensus "Hold" rating and an average target price of $385.25.
Vaxcyte rises as pneumococcal shot establishes ‘new competitive moat’ vs. Pfizer, Merck
Vaxcyte's investigational pneumococcal conjugate vaccine, VAX-31, has shown "near best-case scenario" data in a Phase 3 trial, exceeding expectations and positioning the company to challenge Pfizer and Merck in the $8 billion market. The trial demonstrated VAX-31's non-inferiority to existing vaccines and superiority on three unique serotypes, leading to a significant surge in Vaxcyte's share price. Analysts believe VAX-31 sets a new competitive standard, potentially offering the broadest protection against pneumococcal disease.
Zai Lab Reports Q2 2026 Results: Full Earnings Call Transcript
Zai Lab reported an 11% sequential increase in net product revenue to $105.8 million in Q2 2026, maintaining commercial profitability. The company is transitioning into a global biopharmaceutical firm, with its first U.S. regulatory submission expected next year, driven by significant R&D progress in potential best-in-class assets like Zozi and ZL1503. Zai Lab aims for a return to meaningful year-on-year growth in 2027, with a potential first U.S. product launch in 2028, supported by disciplined capital allocation and $717.5 million in cash.
Cantor Fitzgerald reiterates Amgen stock Neutral rating at $400 By Investing.com
Cantor Fitzgerald has reiterated a Neutral rating on Amgen Inc. (NASDAQ:AMGN) with a price target of $400, noting the stock currently trades slightly above this at $403. The firm cited Amgen's solid commercial execution, 9.1% revenue growth, and impressive 71.9% gross profit margin. Despite a relatively quiet catalyst calendar, Amgen is seen as a consensus long position, with InvestingPro analysis suggesting the stock is undervalued and in "GREAT" financial health.
Cantor Fitzgerald reiterates Amgen stock Neutral rating at $400 By Investing.com
Cantor Fitzgerald has reaffirmed its Neutral rating on Amgen Inc. (NASDAQ:AMGN) with a $400 price target, noting the company's solid commercial execution and strong revenue growth. Despite the stock trading slightly above this target, InvestingPro analysis suggests it may be undervalued. Recent successful Phase 3 trial results for dazodalibep in Sjögren’s disease have generated mixed but generally positive analyst responses, though the company faces a quiet catalyst calendar until late 2026.
Precision Medicine: A 62-Asset Test Of Whether The Vertex Model Travels Beyond Oncology
In Vivo has identified 62 non-oncology precision medicine assets currently undergoing clinical trials, with gene therapy being the predominant intervention. This analysis explores whether the successful Vertex Pharmaceuticals model, known for its precision medicine approach in oncology, can be effectively applied to other therapeutic areas. The article examines the implications of this finding for the broader life sciences industry.
Scotiabank raises target for Amgen stock from USD 450.00 to USD 500.00
Scotiabank has increased its price target for Amgen (AMGN) stock from $450.00 to $500.00, maintaining an outperform rating. This adjustment follows strong second-quarter revenues of $10.05 billion, which surpassed analyst estimates, and positive Phase 3 study results for its drug dazodalibep. Despite the raised target, Amgen's stock remains below its 52-week high.
How Investors Are Reacting To Regeneron Pharmaceuticals (REGN) Sanofi Alliance Expansion
Regeneron Pharmaceuticals announced early data for two new therapies and an expanded alliance with Sanofi, potentially adding up to US$8 billion in milestones. This expansion aims to diversify Regeneron's revenue beyond its current blockbusters and deepen its immunology pipeline. Investors are evaluating how this collaboration and new drug data will influence the company's long-term growth and address pressure on its existing EYLEA franchise.
Amgen announces Sjögren's results as Amgen stock trades flat at EUR 358.63
Amgen stock traded flat at EUR 358.63 in weekend trading on October 4, 2026, following its Xetra close of the same value on October 2, 2026. This comes after the company announced positive topline phase 3 results for dazodalibep in moderate-to-severe systemic Sjögren's disease on September 22, 2026. The next Xetra session for Amgen is scheduled for October 5, 2026.
Amgen Inc Stock Futures,Dec-202 (SAMGN=F) Interactive Stock Chart
This page provides an interactive stock chart for Amgen Inc Stock Futures, specifically for the December 202 (SAMGN=F) contract. It displays the current price, a summary, news, historical data, and various chart customization options. The page also includes general market data for Canada and other global markets.
NOVARTIS AG N (NOTA.F) Q2 FY2026 earnings call transcript
Novartis reported strong Q2 FY2026 performance, with net sales up 1% and core operating income flat, driven by key growth brands like KISQALI, Cosentyx, and Scemblix. The company reaffirmed its full-year 2026 guidance, expecting low single-digit net sales growth and a low single-digit decline in core operating income. Novartis highlighted significant pipeline advancements, including updated KISQALI data, progress in rare disease programs like del-brax, and anticipated regulatory milestones and readouts for various assets in the second half of the year.
Werewolf Therapeutics Inc (HOWL) Stock Price, Quote, News & History
This article provides comprehensive information on Werewolf Therapeutics Inc. (HOWL), including its stock price, key statistics, recent news, financial data, and analyst ratings. It highlights the company's biopharmaceutical focus and its recent merger with Ambros Therapeutics.
David J. Taylor Purchases Amgen and Home Depot Stocks, Sells Marathon Petroleum
David J. Taylor, a representative from Ohio's 2nd congressional district, recently updated his investment portfolio. He purchased common stock in biopharmaceutical company Amgen Inc. and home improvement retailer Home Depot, Inc. Concurrently, Taylor sold common stock in Marathon Petroleum Corporation, with all transactions valued between $1,001 and $15,000.
Amgen (NASDAQ:AMGN) Stock Purchase Disclosed by Rep. David Taylor
Rep. David Taylor (Republican-Ohio) recently disclosed purchasing between $1,001 and $15,000 worth of Amgen (NASDAQ:AMGN) shares on September 22, 2026, through his trust-linked 401(k) account. This transaction follows Amgen's strong quarterly results, which exceeded expectations with an EPS of $6.29 and revenue of $10.05 billion, a 9.5% year-over-year increase. Despite a consensus "Hold" rating from analysts and institutional ownership of 76.5%, the company also declared a quarterly dividend of $2.52 per share.
Home Depot (NYSE:HD) Stock Purchase Reported by Rep. David Taylor
Rep. David Taylor (R-Ohio) recently purchased between $1,001 and $15,000 worth of Home Depot (NYSE:HD) stock on September 22, 2026, within a trust-linked 401(k) account. This transaction was part of several trades, including buying Amgen shares and selling Marathon Petroleum stock on the same day. Home Depot's latest quarterly earnings exceeded expectations, reporting $4.92 EPS against a $4.73 consensus, and analysts currently rate the stock with a "Moderate Buy" consensus and an average price target of $375.18.
David J. Taylor Purchases Amgen and Home Depot Stocks, Sells Marathon Petroleum
Congressman David J. Taylor has recently adjusted his investment portfolio by purchasing shares in Amgen Inc. and Home Depot, Inc., while selling shares in Marathon Petroleum Corporation. All transactions, valued between $1,001 and $15,000 each, were executed on September 22, 2026, and reported on October 1, 2026. Amgen, a biopharmaceutical company, is noted for its strong returns and undervalued status according to InvestingPro analysis, having raised its dividend for 15 consecutive years.
AbbVie joins US government pilot to test drug discount rebates
AbbVie will participate in a US government pilot program to test a new rebate system for discounted medicines under the 340B program, starting January 1, 2027. This initiative aims to improve pricing transparency and prevent duplicate discounts as new Medicare-negotiated drug prices take effect. Other major pharmaceutical companies like Amgen, AstraZeneca, Pfizer, and Bristol Myers Squibb are also part of this federal pilot.
AbbVie joins US government pilot to test drug discount rebates
AbbVie will participate in a U.S. government pilot program starting January 1, 2027, to test a new rebate system for discounted medicines under the 340B program. This initiative aims to improve pricing transparency and prevent duplicate discounts for drugs like Imbruvica, Linzess, and Vraylar, especially as new Medicare-negotiated drug prices take effect. Other major pharmaceutical companies like Amgen, AstraZeneca, Pfizer, and Bristol Myers Squibb are also approved for this federal pilot.
Amgen Inc. (AMG.DE) Stock Price, News, Quote & History
This article provides detailed financial information for Amgen Inc. (AMG.DE), including its current stock price, historical data, key statistics, and company overview. It highlights the company's product portfolio, collaborations, and financial performance metrics like revenue, earnings, and profitability. The page also features comparative returns against the S&P 500 benchmark.
Long-acting EVO301 Shows Promise in Proof-of-concept AD Study
Evommune, Inc.'s EVO301, a long-acting injectable fusion protein, demonstrated promising results in a Phase 2a proof-of-concept study for atopic dermatitis (AD). The drug showed a clear therapeutic signal and a favorable safety profile, achieving significant reductions in Eczema Area and Severity Index (EASI) scores. EVO301's mechanism involves inhibiting IL-18, engaging multiple inflammatory pathways beyond just Th2, suggesting a broad applicability for AD treatment.
Ohio Rep. David Taylor Bought Up to $45K Worth of Amgen Stock
Ohio Representative David Taylor recently purchased Amgen (NASDAQ: AMGN) stock valued between $3,003 and $45,000, with the transaction occurring on September 22, 2026. This adds to his extensive trading activity over the past three years, totaling over $357 thousand, and includes trades in companies like Microsoft and Home Depot. The article highlights the importance of congressional transaction disclosures under the STOCK Act, which aims to prevent insider trading by elected officials.
Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
Johnson & Johnson announced new two-year data from the Phase 3 ICONIC-TOTAL study demonstrating ICOTYDE® (icotrokinra) provides sustained skin clearance and a favorable safety profile for difficult-to-treat plaque psoriasis, particularly in high-impact areas like the scalp and genitals. The data, presented at EADV 2026, showed significant improvements in skin clearance rates through Week 112 for adult and adolescent patients. ICOTYDE is a targeted oral peptide that blocks the IL-23 receptor, offering a new powerful first-line systemic therapy.
Amgen Inc (AMGN) Shares Fall 3.4% -- GF Value Says Still Overval
Amgen Inc (AMGN) shares dropped 3.4% to $407.27, but GuruFocus's GF Value™ assessment still indicates the stock is overvalued by 10.8% compared to its estimated fair value of $367.70. Despite a strong GF Score™ of 86/100, the company shows concerns in financial strength and momentum, and insiders have sold $29.3 million worth of shares over the past year without any purchases. Investors are advised to exercise caution due to the overvaluation and insider selling trends.
Amgen (AMGN) Stock Dips While Market Gains: Key Facts
Amgen (AMGN) stock closed down 3.38% at $407.27, underperforming the broader market which saw gains in the S&P 500, Dow, and Nasdaq. Analysts project a 0.89% increase in EPS and 3.68% growth in revenue for the upcoming quarter. Despite its current Zacks Rank of #3 (Hold) and a favorable Forward P/E ratio compared to its industry, the Medical - Biomedical and Genetics industry, to which Amgen belongs, ranks in the bottom 27% of all industries.
Amgen Inc Stock (AMGN) Closed Down by 3.38% on Oct 1: What Investors Need To Know
Amgen Inc. (AMGN) stock closed down by 3.38% on October 1st, attributed to profit-taking after a multi-year rally, broad market dynamics, and investor caution regarding pipeline assets and operational headwinds like biosimilar competition. Despite strong core commercial volume growth and positive late-stage readouts for some candidates, the company faces significant debt and long-term risks from biosimilar market entry for key legacy products. Technical indicators are neutral, and fundamental analysis shows strong annual revenue and net profit within the Pharmaceuticals & Medical Research industry, though analysts have rated the company as "Hold."
More Than Skin Deep: Understanding Discoid Lupus Erythematosus
Discoid lupus erythematosus (DLE) is an autoimmune skin condition and the most common subtype of chronic cutaneous lupus erythematosus (CLE), causing visible and often permanent skin changes. The condition significantly impacts patients' daily lives due to limited treatment options and ongoing symptoms. Researchers are working to understand the underlying immune pathways, particularly the role of plasmacytoid dendritic cells and type I interferons, to develop more targeted therapies.
Amgen (NASDAQ:AMGN) Scores Late-Stage Immunology Win
Amgen's late-stage immunology candidate for an autoimmune condition reported positive topline results, contributing to a broader market rotation towards healthcare stocks in early October. This win strengthens Amgen's pipeline and positions the company favorably in a market increasingly valuing resilient business models. The company is also focusing on a late-stage obesity candidate and maintains a diversified portfolio across several therapeutic areas and a biosimilars business.
Invivyd Inc (IVVD-Q) Stock Price and News
This article provides detailed stock information for Invivyd Inc (IVVD-Q) including real-time quotes, historical data, and recent news headlines. It covers the company's financial metrics, analyst ratings, and updates on its biopharmaceutical development, particularly concerning its COVID-19 antibody trials and regulatory status. The article also lists various news entries from sources like Tipranks and GlobeNewswire, highlighting key events such as leadership changes, clinical trial results, and Nasdaq listing concerns.
Amgen reports Phase 3 results and Amgen stock trades at EUR 371.13
Amgen reported positive Phase 3 results for dazodalibep in systemic Sjogren's disease on September 22, 2026, which showed statistically significant and clinically meaningful improvement. The company also announced strong second-quarter revenue of USD 10.05 billion, up 9.50 percent, and maintained its full-year adjusted earnings-per-share guidance. Amgen stock was trading at EUR 371.13 at Lang & Schwarz on October 1, 2026, slightly down from its prior close, with its next earnings date scheduled for November 2, 2026.
Quest Diagnostics Incorporated (DGX) Latest Stock News & Headlines
This article provides the latest news and headlines for Quest Diagnostics (DGX), including its stock performance and recent announcements. Key updates include a declared cash dividend, clinical performance demonstrations for Haystack MRD®, and a new heart screening program in Florida. The company's stock has seen significant gains year-to-date, despite concerns about potential Medicare payment cuts.
Morgan Stanley Names 3 Biotech Breakthroughs That Offer Investment Opportunities
Morgan Stanley has identified three significant biotech breakthroughs that present investment opportunities: Alzheimer's drugs, gene editing, and artificial intelligence (AI). The bank forecasts the Alzheimer's drug market at $70 billion and a $10 billion in-vivo gene editing market by 2035. For AI, Morgan Stanley favors companies supplying data, tools, and computing power, rather than drug developers, due to the unproven nature of AI raising drug success rates.
Pliant Therapeutics names David Raben as chief medical officer By Investing.com
Pliant Therapeutics has announced the appointment of David Raben, M.D., as its new Chief Medical Officer. Dr. Raben brings over 30 years of experience in oncology drug development, clinical care, and academic translational research, and will support the advancement of PLN-101095, with trial readouts expected in 2027. In connection with his new role, Raben was granted non-statutory stock options to purchase 575,000 shares of common stock.
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
Pliant Therapeutics has announced the appointment of David Raben, M.D., as its new Chief Medical Officer. Dr. Raben brings over 30 years of experience in academic research, clinical care, and oncology drug development, having previously held senior roles at Bicara Therapeutics, Amgen, and Genentech. His expertise in advancing targeted oncology therapies will be crucial as Pliant Therapeutics progresses its lead program, PLN-101095, through clinical trials.
Halozyme Therapeutics, Inc. Appoints James "Jim" Daly to Its Board of Directors
Halozyme Therapeutics, Inc. has announced the appointment of James "Jim" Daly to its Board of Directors. Mr. Daly is a highly experienced biopharmaceutical executive with over three decades of commercial leadership, including successful launches of respiratory, oncology, and immunology therapies. He has previously served on Halozyme's board and held senior commercial roles at Incyte Corporation, Amgen, and Glaxo Wellcome/GlaxoSmithKline.
Bristol Myers trial revisions shake confidence in new class of fibrosis drugs
Bristol Myers Squibb has altered its late-stage trial for the pulmonary fibrosis drug admilparant due to liver-related safety events, including one patient death. While the company and analysts suggest the safety concerns might be "overdone" and not necessarily drug-related, the revisions have reignited historical concerns about liver toxicity within the LPA1R inhibitor drug class. The trial's results, expected by year-end, are highly anticipated to clarify the safety profile of admilparant and similar drugs.
Is Amgen (AMGN) Undervalued Following Its Phase 3 Sjögren's Disease Trial Update?
Amgen (AMGN) has reported positive Phase 3 trial data for dazodalibep in Sjögren's disease, leading to a significant increase in its share price. Despite this, some analyses suggest the stock is overvalued due to challenges in the obesity market, regulatory hurdles, and erosion of legacy drug sales. Conversely, Simply Wall St's DCF model indicates Amgen might be undervalued based on future cash flow estimates, highlighting a split in expert opinion regarding the company's true worth.
H.C. Wainwright reiterates Zenas Biopharma stock rating ahead of PDUFA By Investing.com
H.C. Wainwright has reiterated a Buy rating and a $44.00 price target for Zenas Biopharma (NASDAQ: ZBIO) as the company approaches the PDUFA target action date of May 27, 2027, for its drug obexelimab. The firm highlights the drug's potential for at-home administration and lower infection risk compared to existing therapies. Other analysts maintain a "Strong Buy" consensus, though InvestingPro analysis suggests the stock may be overvalued at current levels despite recent gains.
Verastem, Inc. (VSTM) stock price, news, quote and history
This article provides detailed financial information, news, and historical data for Verastem, Inc. (VSTM). It covers the company's stock performance, key financial metrics, product candidates in development for cancer treatment, and analyst insights, including price targets and recommendations.
Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody
Amgen's monoclonal antibody daxdilimab showed promising results in a phase 2 study for discoid lupus, reducing disease severity by 6 points at the lower dose. This 50% reduction in lupus disease area and severity is considered a significant improvement for patients. The drug, acquired from Horizon Therapeutics, is now being prepared for a registrational phase of development despite an earlier failure in systemic lupus erythematosus.
Robert Hunter Named UnitedHealth (UNH) Insurance President
Robert Hunter has been named the new president of UnitedHealth Group's insurance division, UnitedHealthcare. This internal promotion signals a continuity of strategy for the company, which is focused on recovering from past medical cost pressures. Hunter inherits a division that has achieved earnings recovery primarily through cost control, with revenue growth having almost stopped, posing a challenge for future expansion.
Has Mesoblast (ASX:MSB) Cleared a Key FDA Manufacturing Hurdle for Ryoncil?
Mesoblast has secured FDA approval for a new potency assay (TIBA) for its cell therapy Ryoncil, which is crucial for ensuring consistent product quality in commercial batches. This approval addresses a significant hurdle in cell therapy manufacturing by allowing the company flexibility to scale production or change facilities while maintaining FDA compliance. While important for operational efficiency, the article notes that larger drivers for Mesoblast's stock will be Ryoncil sales growth, adult label expansion, and upcoming late-stage pipeline readouts.
Amgen Readies Daxdilimab For Phase III In Discoid Lupus After Mid-Stage Trial
Amgen is preparing its rare disease asset daxdilimab for Phase III trials in discoid lupus, following positive mid-stage results. The drug, acquired through the Horizon purchase, targets a condition affecting approximately 28 out of every 100,000 people in the US. This move signals Amgen's advancement in the immune disorders therapeutic area.
Computer-Aided Drug Discovery - Global Strategic Business Report: Capitalize on 11% CAGR as AI-led CADD surges from $3.2B in 2025 to $6.7B by 2032—benchmark Bayer, Charles River Laboratories, Pharmaron and Chemical Computing Group to secure growth.
The global computer-aided drug discovery (CADD) market is projected to grow from $3.2 billion in 2025 to $6.7 billion by 2032, driven by an 11% CAGR. This growth is fueled by advancements in AI, machine learning, cloud computing, and multi-omics, which are accelerating drug discovery, reducing costs, and enabling personalized therapies. The report details market trends, growth drivers, and segmented forecasts, highlighting key players like Bayer and Charles River Laboratories.
Amgen Inc (AMGN) Shares Surge 1.3% -- What GF Score of 87 Tells Investors
Amgen Inc (AMGN) shares surged 1.3% to $423.64, showing significant year-to-date and past-year gains. Despite this, GuruFocus assesses AMGN as "Modestly Overvalued" with a GF Value™ of $367.64 and a P/E ratio above its historical median. The company holds a strong GF Score™ of 87/100 due to excellent profitability and growth, but faces concerns regarding financial strength and substantial insider selling.
What Is Regeneron Pharmaceuticals (REGN) Facing After A Rival Matched Its Key Eye Drug?
Kodiak Sciences recently announced Phase 3 data for its eye drug Zenkuda, showing it matched Regeneron Pharmaceuticals' Eylea in treating macular degeneration, with the added benefit of less frequent dosing (twice a year versus Eylea's typical every eight weeks). This development puts pressure on Regeneron's Eylea franchise, highlighting the need for diversification and the importance of its broader pipeline beyond this key eye drug. Regeneron's strategy involves leveraging durable cash flows from core franchises to fund a wide pipeline, with new assets like Eylea HD and other immunology and oncology programs aimed at reducing reliance on a single product.
Amgen (NASDAQ:AMGN) Stock: Dazodalibep's Phase 3 Win Targets a Disease With No Approved Medicines
Amgen's drug dazodalibep has successfully completed a Phase 3 trial (OASIZ 301) for moderate-to-severe systemic Sjögren's disease, a condition with no FDA-approved medicines. The trial met its primary endpoint, showing statistically significant improvements in disease activity. This late-stage win strengthens Amgen's immunology pipeline, despite financial challenges from biosimilar competition for some of its existing products.
Amgen (NASDAQ:AMGN) Reports Positive Dazodalibep Data in Sjogren's
Amgen reported positive topline results from its pivotal dazodalibep study for adults with moderate-to-severe systemic Sjogren's disease, showing significant improvement on the ESSDAI endpoint. This result strengthens Amgen's autoimmune assets, which were acquired through the Horizon Therapeutics acquisition, and diversifies its growth strategy beyond obesity and biosimilars. Dazodalibep is a fusion protein that targets inflammation and autoantibody production, addressing an unmet need in Sjogren's disease where no approved therapies target its underlying biology.
